Additionally, we offer an overview of the recent advancements in KLRG1 inhibitor development for tumor immunotherapy, underscored by the promising synergistic efficacy of KLRG1 inhibitors combined with other targeted inhibitors. Here, KLRG1 is linked to neoplasm.